- Conditions
- Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
- Interventions
- Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet
- Device
- Lead sponsor
- Jaguar LAA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Clinical trials in Nashville, Tennessee
This page shows live ClinicalTrials.gov search results for Nashville, Tennessee, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Nashville
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- Camizestrant, Ribociclib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 12
- States / cities
- Duarte, California • Palo Alto, California • Marietta, Georgia + 9 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 60
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 55 more
- Conditions
- Type 2 Diabetes
- Interventions
- Cagrilintide, Semaglutide, Tirzepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,024 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 117
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 96 more
- Conditions
- Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation (PAF)
- Interventions
- Sphere-9 Catheter Ablation
- Device
- Lead sponsor
- Medtronic Cardiac Ablation Solutions
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
- Interventions
- Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 2,175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2038
- U.S. locations
- 999
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more
- Conditions
- Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Advanced Solid Tumors
- Interventions
- AMG 305
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Duarte, California • Hackensack, New Jersey • New York, New York + 3 more
- Conditions
- Postoperative Nausea, Postoperative Vomiting
- Interventions
- AW-D Clinical Decision Support Tool
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19,480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Cancer
- Interventions
- Multi-Cancer Early Detection Test (Galleri®)
- Device
- Lead sponsor
- GRAIL, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 50,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 72
- States / cities
- Fort Smith, Arkansas • Auburn, California • Davis, California + 51 more
- Conditions
- Open Midline Laparotomy
- Interventions
- Phasix™ Mesh
- Device
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 17 more
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
- Interventions
- CB-010, Cyclophosphamide, Fludarabine
- Genetic · Drug
- Lead sponsor
- Caribou Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 27 more